Evidence map›Paper›PMID 41908149›Full record

ArticleNeuro-oncology advances

Adoptive cellular therapy prevents reconstitution of myeloid-derived suppressor cells in the glioma tumor microenvironment.

John W Figg, Caitland Love, Sofia Stansbury, Dan Jin, Connor Francis, Bayli DiVita Dean, Alexandra Reid, Mia Engelbart, Illeana West, Laura Falceto Font and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuro-oncology advances. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Rewriting microenvironment immunity in glioblastoma.Molecular therapy. Oncology · 2026
    Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

John W FiggPreston A. Wells, Jr. Center for Brain Tumor Therapy, Lillian S. Wells Department of Neurosurgery, University of Florida, Gainesville, FL, USA.ORCID https://orcid.org/0000-0002-9869-1094
Caitland LovePreston A. Wells, Jr. Center for Brain Tumor Therapy, Lillian S. Wells Department of Neurosurgery, University of Florida, Gainesville, FL, USA.
Sofia StansburyPreston A. Wells, Jr. Center for Brain Tumor Therapy, Lillian S. Wells Department of Neurosurgery, University of Florida, Gainesville, FL, USA.
Dan JinPreston A. Wells, Jr. Center for Brain Tumor Therapy, Lillian S. Wells Department of Neurosurgery, University of Florida, Gainesville, FL, USA.ORCID https://orcid.org/0000-0001-6323-9674
Connor FrancisPreston A. Wells, Jr. Center for Brain Tumor Therapy, Lillian S. Wells Department of Neurosurgery, University of Florida, Gainesville, FL, USA.
Bayli DiVita DeanPreston A. Wells, Jr. Center for Brain Tumor Therapy, Lillian S. Wells Department of Neurosurgery, University of Florida, Gainesville, FL, USA.
Alexandra ReidPreston A. Wells, Jr. Center for Brain Tumor Therapy, Lillian S. Wells Department of Neurosurgery, University of Florida, Gainesville, FL, USA.
Mia EngelbartPreston A. Wells, Jr. Center for Brain Tumor Therapy, Lillian S. Wells Department of Neurosurgery, University of Florida, Gainesville, FL, USA.
Illeana WestPreston A. Wells, Jr. Center for Brain Tumor Therapy, Lillian S. Wells Department of Neurosurgery, University of Florida, Gainesville, FL, USA.
Laura Falceto FontPreston A. Wells, Jr. Center for Brain Tumor Therapy, Lillian S. Wells Department of Neurosurgery, University of Florida, Gainesville, FL, USA.
Diana FeierPreston A. Wells, Jr. Center for Brain Tumor Therapy, Lillian S. Wells Department of Neurosurgery, University of Florida, Gainesville, FL, USA.
Ghaidaa EbrahimPreston A. Wells, Jr. Center for Brain Tumor Therapy, Lillian S. Wells Department of Neurosurgery, University of Florida, Gainesville, FL, USA.
Rachael BesseyPreston A. Wells, Jr. Center for Brain Tumor Therapy, Lillian S. Wells Department of Neurosurgery, University of Florida, Gainesville, FL, USA.
David HilfertyPreston A. Wells, Jr. Center for Brain Tumor Therapy, Lillian S. Wells Department of Neurosurgery, University of Florida, Gainesville, FL, USA.
Oleg YegorovPreston A. Wells, Jr. Center for Brain Tumor Therapy, Lillian S. Wells Department of Neurosurgery, University of Florida, Gainesville, FL, USA.
Changling YangPreston A. Wells, Jr. Center for Brain Tumor Therapy, Lillian S. Wells Department of Neurosurgery, University of Florida, Gainesville, FL, USA.
Kaytora Long-JamesPreston A. Wells, Jr. Center for Brain Tumor Therapy, Lillian S. Wells Department of Neurosurgery, University of Florida, Gainesville, FL, USA.
Duane A MitchellPreston A. Wells, Jr. Center for Brain Tumor Therapy, Lillian S. Wells Department of Neurosurgery, University of Florida, Gainesville, FL, USA.
Catherine T FloresPreston A. Wells, Jr. Center for Brain Tumor Therapy, Lillian S. Wells Department of Neurosurgery, University of Florida, Gainesville, FL, USA.

Funding

The role of adoptive cellular therapy on myeloid-derived suppressor cell depletion in gliomaF30CA298656 · NCI · UNIVERSITY OF FLORIDA · PI John W Figg · 2025 to 2026
$88k
NCI NIH HHS F30 CA298656
6 · The paper itself

Abstract

Background: Glioblastoma (GBM) is an aggressive brain cancer infiltrated by immunosuppressive myeloid-derived suppressor cells (MDSCs) and confers poor prognosis. To address this, our group developed an adoptive cellular therapy platform specifically for primary central nervous system (CNS) malignancies that yielded significant survival benefits against multiple brain cancer models. Preclinically, this platform establishes proof-of-concept for lymphodepletion achieved through host conditioning with total body irradiation (TBI). While host conditioning is thought to remove immunosuppressive elements, the aim of this study was to determine how immune recovery is affected by adoptive cellular therapy. Methods: The adoptive cellular therapy platform includes myeloablative TBI, hematopoietic stem cell rescue, tumor-specific T cells, and dendritic cell vaccines. KR158B glioma-bearing mice were treated with adoptive cellular therapy and secondary lymphoid organs were evaluated using flow cytometry, spatial genomics, and multiplex protein analysis. Single-cell transcriptomics and trans-well migration assay evaluated the role of CCL12 on MDSC migration. Results: We show that adoptive cellular therapy allows for reconstitution of MDSC and tumor-associated macrophages in secondary lymphoid organs but prevents their accumulation in the tumor microenvironment (TME). This allows for the increased engraftment and activation of T cells within the TME. Next, we show that adoptive cellular therapy decreases CCL12 in the TME and neutralization of TAM-derived CCL12 in vitro inhibits MDSC migration in glioma. Conclusion: These findings suggest a previously unrecognized association between both loss of intratumoral immunosuppressive elements after immunotherapy and TAM-derived CCL12, a chemokine that promotes MDSC migration. Future in vivo studies will evaluate the causal role of CCL12 on MDSC recruitment in glioma.

Indexed as

adoptive immunotherapyCCL12glioblastomaMDSCmigration

Identifiers

PMID41908149
PMCPMC13019303

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.